51
edits
Changes
Jump to navigation
Jump to search
Line 3,532:
Line 3,532: − + − + Line 3,543:
Line 3,543: − + Line 3,569:
Line 3,569: − + − + Line 3,604:
Line 3,604: − + − + − + − | + − + − + − + − | + Line 3,721:
Line 3,721: − + − + − + − | + Line 3,892:
Line 3,892: − + − + − + − | + Line 3,910:
Line 3,910: − + − + − + − | + Line 3,946:
Line 3,946: − + − + − + − | +
Volunteer Assignments and Opportunities (view source)
Revision as of 17:36, 2 October 2023
, 17:36, 2 October 2023updated page assignments
|
|
|-
|-
|Adenoid Cystic Carcinoma||Disease||Katherine Geiersbach
|Adenoid Cystic Carcinoma||Disease||Katherine Geiersbach and Jun Liao
|10/12/02022
|10/12/02022
|
|11/11/2023
|PENDING
|PENDING
|
|
|Secretory Carcinoma||Disease||Hui Chen
|Secretory Carcinoma||Disease||Hui Chen
|10/12/2022
|10/12/2022
|
|11/11/2023
|PENDING
|PENDING
|
|
|-
|-
|Tall Cell Carcinoma with Reversed Polarity||Disease||H. Evin Gulbahce
|Tall Cell Carcinoma with Reversed Polarity||Disease||H. Evin Gulbahce
|
|8/11/2023
|
|10/11/2023
|PENDING
|PENDING
|
|
|
|
|-
|-
|Fibroadenoma||Disease||
|Fibroadenoma||Disease||H. Evin Gulbahce / Patricija Zot
|
|8/11/2023
|
|10/11/2023
|
|
|
|
|Hui Chen
|
|
|
|
|-
|-
|Phyllodes Tumour||Disease||
|Phyllodes Tumour||Disease||H. Evin Gulbahce / Patricija Zot / Emilie Lalonde
|
|8/11/2023
|
|10/11/2023
|
|
|
|
|Hui Chen
|
|
|
|
|
|
|-
|-
|Inflammatory Myofibroblastic Tumour||Disease||
|Inflammatory Myofibroblastic Tumour||Disease||Yajuan Liu
|
|8/11/2023
|
|11/11/2023
|
|
|
|
|Hui Chen
|
|
|
|
|
|
|-
|-
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||
|BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome||Disease||Constance Albarracin
|
|8/11/2023
|
|11/11/2023
|
|
|
|
|Katherine Geiersbach
|
|
|
|
|
|
|-
|-
|Ataxia-Telangiectasia||Disease||
|Ataxia-Telangiectasia||Disease||Evin Gulbahce
|
|8/11/2023
|
|11/11/2023
|
|
|
|
|Katherine Geiersbach
|
|
|
|
|
|
|-
|-
|PALB2-Associated Cancers||Disease||
|PALB2-Associated Cancers||Disease||Katherine Geiersbach
|
|10/2/2023
|
|1/2/2024
|
|
|
|
|Katherine Geiersbach
|
|
|
|